구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp) Genmab / AbbVie·CD20 × CD3 57 trials·t½ ~3 weeks at steady state | ||
|---|---|---|---|
Overview Program | Columvi (glofitamab) | Epkinly (epcoritamab) | Mosunetuzumab |
Overview Company | Roche / Genentech | Genmab / AbbVie | Epizyme, Inc. |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | CD20 × CD3 | CD20 × CD3 | FRα |
Overview Indication | Relapsed or refractory diffuse large B-cell lymphoma | Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma | Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Bivalent CD20 binding increases avidity; obinutuzumab pretreatment debulks circulating B cells to blunt first-dose CRS. | Subcutaneous dosing gives slower Cmax and lower grade ≥3 CRS than IV engagers. | novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas |
Positioning Known limitation | CD20 loss after prior anti-CD20 therapy and T-cell exhaustion. | CD20 antigen loss and exhausted effector T cells after multiple prior lines. | bypassing MHC presentation |
Positioning Development positioning | Competes with Epkinly on schedule and route; fixed duration is its main claim. | Main SC alternative to Columvi, with continuous rather than fixed duration. | — |
MoA Mechanism | Crosslinks CD20 on malignant B cells with CD3 on T cells; the 2:1 geometry stabilizes the synapse and drives T-cell activation and B-cell lysis. | Bispecific binding of CD20 on B cells and CD3 on T cells creates a cytolytic synapse; the silenced Fc prevents Fcγ-receptor-driven off-target activation. | , pharmacokinetic properties, and key clinical efficacy and safety data from the ELM-1 and ELM-2 trials, which supported its approval by the European Medicines Agency (EMA) |
MoA Biomarker | CD20 expression; ctDNA clearance investigational. | CD20 expression; ctDNA MRD investigational. | CD20 RO% was high |
PK/PD Half-life | ~1–2 weeks | ~3 weeks at steady state | — |
PK/PD Species | Cynomolgus monkey, B-cell depletion, cytokine profile, PET-CR | Cynomolgus monkey, Peripheral B-cell depletion, cytokine kinetics, PET response | Mouse, Human |
PK/PD Animal (cat.) | Human, NHP | Human, NHP, In vitro | Human, Mouse |
PK/PD Experiment | Pharmacodynamic | pharmacokinetic | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse | Cynomolgus monkey | Cynomolgus monkey, Mouse, Human |
Toxicology Animal (cat.) | — | — | NHP |
Toxicology Major finding | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | thrombocytopenia [see Adverse Reactions (6 |
Toxicology CRS | CRS ~63%, grade ≥3 ~4% | CRS ~50%, grade ≥3 ~2.5% | 39% |
Clinical Safety signal | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | thrombocytopenia [see Adverse Reactions (6 |
Clinical Selected reported efficacy | ORR 35.3% | ORR 61% | ORR 87.5% |
Clinical Reported ORR | 35.3% | 61% (DLBCL) | 95.0% |
Clinical Reported PFS | — | — | NA |
Clinical Result source | ClinicalTrials.gov NCT04313608 | EPCORE NHL-1 (NCT03625037) | ClinicalTrials.gov NCT03677141 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | — |
Clinical Trial ref | NCT04313608 | NCT03625037 | NCT03677141 |
Preclinical Animal (cat.) | NHP | Human, NHP, Monkey, In vitro | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp) Genmab / AbbVie·CD20 × CD3 57 trials·t½ ~3 weeks at steady state | ||
|---|---|---|---|
Overview Program | Columvi (glofitamab) | Epkinly (epcoritamab) | Mosunetuzumab |
Overview Company | Roche / Genentech | Genmab / AbbVie | Epizyme, Inc. |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | CD20 × CD3 | CD20 × CD3 | FRα |
Overview Indication | Relapsed or refractory diffuse large B-cell lymphoma | Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma | Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Bivalent CD20 binding increases avidity; obinutuzumab pretreatment debulks circulating B cells to blunt first-dose CRS. | Subcutaneous dosing gives slower Cmax and lower grade ≥3 CRS than IV engagers. | novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas |
Positioning Known limitation | CD20 loss after prior anti-CD20 therapy and T-cell exhaustion. | CD20 antigen loss and exhausted effector T cells after multiple prior lines. | bypassing MHC presentation |
Positioning Development positioning | Competes with Epkinly on schedule and route; fixed duration is its main claim. | Main SC alternative to Columvi, with continuous rather than fixed duration. | — |
MoA Mechanism | Crosslinks CD20 on malignant B cells with CD3 on T cells; the 2:1 geometry stabilizes the synapse and drives T-cell activation and B-cell lysis. | Bispecific binding of CD20 on B cells and CD3 on T cells creates a cytolytic synapse; the silenced Fc prevents Fcγ-receptor-driven off-target activation. | , pharmacokinetic properties, and key clinical efficacy and safety data from the ELM-1 and ELM-2 trials, which supported its approval by the European Medicines Agency (EMA) |
MoA Biomarker | CD20 expression; ctDNA clearance investigational. | CD20 expression; ctDNA MRD investigational. | CD20 RO% was high |
PK/PD Half-life | ~1–2 weeks | ~3 weeks at steady state | — |
PK/PD Species | Cynomolgus monkey, B-cell depletion, cytokine profile, PET-CR | Cynomolgus monkey, Peripheral B-cell depletion, cytokine kinetics, PET response | Mouse, Human |
PK/PD Animal (cat.) | Human, NHP | Human, NHP, In vitro | Human, Mouse |
PK/PD Experiment | Pharmacodynamic | pharmacokinetic | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse | Cynomolgus monkey | Cynomolgus monkey, Mouse, Human |
Toxicology Animal (cat.) | — | — | NHP |
Toxicology Major finding | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | thrombocytopenia [see Adverse Reactions (6 |
Toxicology CRS | CRS ~63%, grade ≥3 ~4% | CRS ~50%, grade ≥3 ~2.5% | 39% |
Clinical Safety signal | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | thrombocytopenia [see Adverse Reactions (6 |
Clinical Selected reported efficacy | ORR 35.3% | ORR 61% | ORR 87.5% |
Clinical Reported ORR | 35.3% | 61% (DLBCL) | 95.0% |
Clinical Reported PFS | — | — | NA |
Clinical Result source | ClinicalTrials.gov NCT04313608 | EPCORE NHL-1 (NCT03625037) | ClinicalTrials.gov NCT03677141 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | — |
Clinical Trial ref | NCT04313608 | NCT03625037 | NCT03677141 |
Preclinical Animal (cat.) | NHP | Human, NHP, Monkey, In vitro | — |
추천 비교
추천 비교